Ketamine Therapy | Delray Beach | NeuPath Mind Wellness

Postpartum Depression: When Standard Treatments Are Not Enough

Having a baby is supposed to be one of the most joyful experiences of a person’s life. For many new mothers, it is. But for a significant number, the weeks and months following childbirth bring something unexpected and deeply distressing: a depression that is unlike anything they have experienced before. Postpartum depression affects approximately one in seven new mothers. It is not the baby blues, the mild mood fluctuations that resolve within a couple of weeks after delivery. Postpartum depression is a clinical condition with real neurobiological underpinnings, and for some women it is severe, debilitating, and resistant to standard treatments. This post is for those women, and for the partners, family members, and caregivers who love them and are trying to understand what help actually looks like. What Postpartum Depression Actually Is Postpartum depression is a major depressive episode that occurs within the first year after childbirth. It shares the core features of major depressive disorder, including persistent low mood, loss of interest in activities, fatigue, sleep disturbance, difficulty concentrating, and feelings of worthlessness or guilt, but it occurs in a specific hormonal and life context that shapes both its presentation and its treatment. The dramatic drop in estrogen and progesterone that occurs after delivery is one of the primary biological triggers. These hormones have significant effects on serotonin, dopamine, and GABA signaling in the brain, and their sudden withdrawal can destabilize mood regulation in vulnerable individuals. Sleep deprivation, the demands of newborn care, changes in identity and relationship dynamics, and in some cases a history of depression or trauma all compound the biological vulnerability. Postpartum depression is not a character flaw. It is not evidence of being a bad mother. It is a medical condition with identifiable biological causes that responds to medical treatment. When Standard Treatments Are Not Enough For many women with postpartum depression, first-line treatments including SSRIs and therapy produce adequate relief. But a meaningful proportion of patients do not respond sufficiently to standard care, or find that the treatments available to them are inadequate for their situation for other reasons. Medication concerns during breastfeeding. Many new mothers are reluctant to take antidepressants while breastfeeding due to concerns about medication transfer to the infant. While most SSRIs are considered relatively safe during breastfeeding, the uncertainty creates a real barrier for some patients and their clinicians. Delayed onset of standard treatments. SSRIs take four to six weeks to produce meaningful antidepressant effects. For a mother in the middle of a severe postpartum depression episode, six weeks is a long time to wait, particularly when the demands of caring for a newborn are immediate and relentless. Inadequate response despite treatment. Some women take antidepressants at appropriate doses for appropriate durations and simply do not improve enough. The biological mechanisms driving their postpartum depression may not be primarily serotonergic, meaning SSRIs are targeting the wrong pathway. Severity requiring faster intervention. Severe postpartum depression, particularly when it involves thoughts of self-harm, harm to the infant, or psychotic features, requires rapid and aggressive treatment. Standard antidepressants are not built for this level of urgency. Advanced Treatment Options for Postpartum Depression Zuranolone and Brexanolone Before discussing the treatments available at NeuPath, it is worth acknowledging two relatively new FDA-approved treatments specifically designed for postpartum depression. Brexanolone, approved in 2019 and marketed as Zulresso, is a synthetic form of allopregnanolone, a neurosteroid that modulates GABA receptors. It is administered as a 60-hour continuous IV infusion in a certified healthcare facility and produces rapid antidepressant effects. Access is limited due to the intensive administration requirements and cost. Zuranolone, approved in 2023 and marketed as Zurzuvae, is an oral neurosteroid medication taken once daily for 14 days. It produces antidepressant effects more rapidly than SSRIs and is specifically approved for postpartum depression. It represents a significant step forward in targeted treatment for this condition. These options are worth discussing with your psychiatrist if you have not already explored them. TMS Therapy TMS is an increasingly recognized option for postpartum depression, particularly for women who want to avoid systemic medication while breastfeeding. Because TMS is non-pharmacological, nothing enters the bloodstream, and there is no medication transfer risk to the infant. It is safe to use during breastfeeding and does not require stopping or adjusting any other treatments. The evidence for TMS in postpartum depression is growing. A 2020 systematic review found that TMS produced significant improvement in postpartum depression symptoms with a favorable safety profile. For women who cannot or do not want to use antidepressants, TMS offers a meaningful alternative with a well-established clinical track record. TMS sessions run 19 to 37 minutes, require no recovery time, and can be scheduled around the demands of caring for a newborn. Many patients bring a support person to watch the baby during sessions. Ketamine Therapy Ketamine‘s most distinctive advantage in the context of postpartum depression is speed. While SSRIs take weeks to work and TMS builds gradually over a treatment course, ketamine can produce meaningful antidepressant effects within hours of the first infusion. For women in severe postpartum depression who need rapid relief, this speed is clinically significant. Ketamine also has a growing evidence base specifically in the postpartum context. A 2022 study published in the Journal of Affective Disorders found that ketamine administration following cesarean delivery significantly reduced postpartum depression rates at both one week and six weeks postpartum compared to placebo. The question of ketamine and breastfeeding requires individual discussion with your psychiatrist. Ketamine does transfer into breast milk, and the clinical guidance is evolving. The decision involves weighing the severity of the depression against the breastfeeding consideration, and it is one that should be made in the context of a careful psychiatric evaluation rather than a general rule. Spravato Spravato is not currently FDA-approved specifically for postpartum depression, and its use during breastfeeding carries the same considerations as ketamine. However, for women who meet the criteria for treatment-resistant depression, which some postpartum cases do, Spravato is an insurance-eligible option worth discussing. The

Living with OCD: How Advanced Therapies Are Changing Treatment

Obsessive-compulsive disorder is one of the most misunderstood conditions in psychiatry. Popular culture has reduced it to a quirk, a punchline, or a personality type. The reality for people living with clinical OCD is something far more serious: a relentless cycle of intrusive thoughts and compulsive behaviors that can consume hours of every day, derail careers, strain relationships, and make ordinary life feel impossible. It is also, historically, one of the harder psychiatric conditions to treat effectively. Standard first-line treatments, SSRIs at high doses combined with a specific form of cognitive behavioral therapy called Exposure and Response Prevention, help many patients but leave a significant proportion without adequate relief. That picture is changing. A new generation of advanced treatments, including TMS therapy with an FDA-approved OCD protocol and ketamine therapy, is offering meaningful options to patients who have not responded to standard care. This post covers what those options are, how they work, and how to know whether they might be right for you. Understanding OCD: Beyond the Stereotype OCD is a neurobiological condition characterized by two core features: obsessions and compulsions. Obsessions are unwanted, intrusive thoughts, images, or urges that cause significant distress. They are not simply worries about real-life problems. They are persistent, involuntary mental intrusions that the person experiencing them recognizes as irrational but cannot dismiss. Common obsession themes include contamination and illness, harm to self or others, symmetry and order, religious or moral scrupulosity, and sexual or violent intrusive thoughts. Compulsions are repetitive behaviors or mental acts performed in response to obsessions, with the goal of reducing anxiety or preventing a feared outcome. They provide temporary relief but reinforce the obsessive cycle over time, making the OCD more entrenched rather than less. Common compulsions include hand washing, checking, counting, arranging, seeking reassurance, and mental rituals like praying or reviewing. The defining feature of clinical OCD is not the content of the obsessions or compulsions but the degree to which they consume time and cause distress or functional impairment. By definition, OCD significantly interferes with daily life. Many patients spend four or more hours per day caught in the obsessive-compulsive cycle. Why Standard OCD Treatment Falls Short for Many Patients The gold standard treatment for OCD combines high-dose SSRIs with Exposure and Response Prevention therapy, a structured behavioral treatment in which patients are gradually exposed to their feared triggers while being supported in resisting the compulsive response. ERP is effective. For patients who can access a trained ERP therapist and complete the treatment, response rates are meaningful. But the treatment has real limitations. Trained ERP therapists are not uniformly available. The treatment is demanding and requires significant patient motivation and tolerance for distress. And even with optimal ERP and SSRI treatment, approximately 40 to 60 percent of OCD patients do not achieve adequate symptom relief. For this population, the question of what comes next has historically had very few good answers. That is the gap that advanced treatments are beginning to fill. TMS Therapy for OCD: FDA-Approved and Clinically Meaningful In 2018, the FDA cleared deep TMS therapy for OCD using the Brainsway H7 coil, a milestone that established TMS as a legitimate and evidence-backed treatment option for patients whose OCD has not responded adequately to medication and therapy. The TMS protocol for OCD differs from the depression protocol in an important way. Rather than targeting the left prefrontal cortex as in depression treatment, the OCD protocol targets the anterior cingulate cortex and medial prefrontal cortex, regions of the brain that play a central role in the error-signaling and behavioral inhibition circuits implicated in OCD. The OCD protocol also incorporates a symptom provocation component immediately before stimulation, during which the patient is briefly exposed to their OCD triggers to activate the relevant neural circuits before TMS stimulation is applied. The pivotal trial supporting FDA clearance found that patients receiving active deep TMS for OCD experienced significantly greater symptom reduction than those receiving sham treatment, with 38.1 percent of active treatment patients achieving a clinically meaningful response compared to 11.1 percent in the sham group. Real-world outcomes in clinical settings have generally been consistent with or more favorable than these trial results. TMS for OCD is non-invasive, requires no anesthesia, causes no systemic side effects, and fits into a normal daily routine. Sessions run approximately 20 minutes. Patients drive themselves to and from treatment and return to their normal activities immediately afterward. Ketamine Therapy for OCD Ketamine’s role in OCD treatment is less established than its role in depression, but the emerging evidence is genuinely promising. Several clinical trials have found that IV ketamine produces rapid and meaningful reductions in OCD symptoms, sometimes within hours of a single infusion. The mechanism appears related to ketamine’s effects on glutamate signaling in the cortico-striato-thalamo-cortical circuits that drive OCD symptomatology, circuits that are not directly targeted by serotonergic medications. A 2023 crossover trial found that a single ketamine infusion produced significantly greater OCD symptom reduction than placebo, with effects lasting several days to weeks after the infusion. For patients in acute OCD distress who need rapid relief, or for those who have not responded to TMS or SSRI trials, ketamine represents a meaningful option worth discussing with a psychiatrist. Ketamine for OCD is not yet FDA-approved for that specific indication, meaning it is used off-label. This is the same status ketamine held for depression for many years before its evidence base became too strong to ignore. The trajectory of the research suggests OCD may follow a similar path. Who Is a Good Candidate for Advanced OCD Treatment? Advanced treatments like TMS and ketamine are most appropriate for patients who fit the following profile: You do not need to have tried every possible medication or exhausted every possible therapy before these options are available to you. But a documented history of standard treatment attempts is typically part of the clinical picture that makes advanced treatment appropriate. OCD Treatment at NeuPath Mind Wellness At NeuPath Mind Wellness, we offer both TMS therapy

What Is Treatment-Resistant Depression? Signs, Causes, and Options

Depression is one of the most common psychiatric conditions in the world, and for most people who develop it, treatment works. A course of antidepressants, therapy, or a combination of both produces meaningful improvement and allows them to get on with their lives. But for a substantial minority of patients, that is not what happens. The first medication does not work. The second one does not work either. Months pass, sometimes years, and the depression persists despite every reasonable effort to treat it. This is not a failure of willpower or a sign that the patient is beyond help. It is a recognized clinical condition with a name, a definition, and a specific set of advanced treatment options designed precisely for this situation. It is called treatment-resistant depression, and understanding what it is, why it happens, and what can be done about it is the first step toward finding a way through it. What Is Treatment-Resistant Depression? Treatment-resistant depression, commonly abbreviated as TRD, is defined as major depressive disorder that has not responded adequately to at least two antidepressant trials conducted at adequate doses and for adequate durations, typically at least four to six weeks each. The key word in that definition is adequately. A medication trial that was cut short because of side effects, or one that was prescribed at a subtherapeutic dose, may not count as a genuine trial. When psychiatrists assess whether a patient meets the criteria for TRD, they look carefully at the history of previous treatments to determine whether each one was given a genuine opportunity to work. By this definition, approximately 30 percent of patients with major depressive disorder meet the criteria for treatment-resistant depression. That is a significant proportion of a very common condition, which means TRD affects millions of people in the United States alone. Signs You May Have Treatment-Resistant Depression TRD does not always announce itself clearly. Many patients spend years cycling through medications without anyone explicitly naming what is happening. The following signs suggest that what you are dealing with may be treatment-resistant depression rather than undertreated or mismanaged depression. You have tried two or more antidepressants at full doses without adequate improvement. This is the clinical definition. If two or more medications have been tried at therapeutic doses for sufficient durations and neither has produced remission, TRD is the working diagnosis. Your depression has been present for more than two years. Chronic depression that persists despite treatment attempts is a strong indicator of treatment resistance. You experience partial improvement but never full remission. Many patients with TRD feel somewhat better on medication but never reach a state where their depression is genuinely in remission. Partial response is common in TRD and is clinically meaningful because it suggests the underlying biology is not fully responsive to the treatments being tried. Your depression keeps returning despite treatment. Recurrent depression that returns quickly after periods of improvement, even when medication is continued, can reflect a treatment-resistant pattern. You have significant functional impairment despite treatment. If depression is still significantly affecting your work, relationships, and daily life despite ongoing treatment, the treatment is not doing enough. You have been told you have a complicated or atypical presentation. Depression with psychotic features, bipolar depression mistaken for unipolar depression, or depression with significant anxiety comorbidity can all be harder to treat and more likely to present as treatment-resistant. Why Does Treatment-Resistant Depression Happen? TRD is not a single condition with a single cause. It is a clinical presentation that can arise from several different underlying factors, often in combination. Genetic factors. The cytochrome P450 enzyme system governs how your liver metabolizes most psychiatric medications. Genetic variants in these enzymes can make you a poor metabolizer, meaning drugs build up to levels that cause side effects before reaching therapeutic efficacy, or an ultra-rapid metabolizer, meaning drugs clear your system before they can work. Pharmacogenomic testing through GeneSight can identify these variants and guide medication selection accordingly. Misdiagnosis. A significant proportion of patients diagnosed with treatment-resistant unipolar depression are actually experiencing bipolar depression. Antidepressants alone are not the appropriate treatment for bipolar depression and can in some cases worsen the condition. A thorough diagnostic re-evaluation is an important early step when TRD is suspected. Comorbid conditions. Untreated anxiety disorders, PTSD, ADHD, substance use disorders, chronic pain, and thyroid dysfunction can all interfere with antidepressant response and make depression appear treatment-resistant when the real issue is an inadequately addressed comorbidity. Biological heterogeneity of depression. Depression is not one disease. It is a clinical syndrome with multiple underlying biological subtypes, some of which respond well to serotonergic medications and some of which do not. Patients whose depression is driven primarily by glutamatergic dysfunction, neuroinflammation, or HPA axis dysregulation may not respond to SSRIs or SNRIs regardless of dose or duration, because those medications do not address the underlying mechanism driving their symptoms. Psychosocial factors. Chronic stress, trauma, poverty, social isolation, and adverse life circumstances can sustain depression through pathways that are not fully addressed by pharmacotherapy alone. A medication cannot fix a life situation, and when the context of a patient’s life is perpetuating their depression, medication resistance is the predictable result. What Are the Treatment Options for TRD? The good news about treatment-resistant depression is that the emergence of advanced treatment options over the last two decades has fundamentally changed the prognosis for patients who previously had very few effective options. Pharmacogenomic Testing Before trying another antidepressant, GeneSight genetic testing can reveal whether genetic factors in your medication metabolism have been contributing to your treatment failures. The test analyzes your DNA and categorizes every major psychiatric medication based on how your genes predict you will respond to it. For patients who have been cycling through medications without understanding why none of them work, this information can be genuinely transformative. TMS Therapy Transcranial Magnetic Stimulation is FDA-approved for treatment-resistant depression and works through a completely different mechanism than antidepressants. Rather than altering brain chemistry through the bloodstream, TMS

Discover a new path to Mental Health and Wellness

Discover a new path to Mental Health and Wellness

ELEVATED MENTAL HEALTH CARE IN DELRAY BEACH

OUR SERVICES

KETAMINE TREATMENT

SPRAVATO TREATMENT

INTEGRATIVE MENTAL HEALTH AND PSYCHIATRIC SERVICES

TMS THERAPY

WELLNESS THAT WORKS

THE NEUPATH MIND WELLNESS DIFFERENCE

iNSURANCE aCCEPTED

RESOURCES AND NEWS

SCHEDULE A CONSULTATION